By Chris Centeno, MD / January 7, 2020
As you may know, we’ve been performing lab-based and clinical research for many years. Two of our most recent studies are for patients with ACL and rotator cuff tears. Both of these research projects will soon be completed, so this is your last chance to get somebody advanced bone marrow concentrate care as part of a study.
Study Designs
Both of these studies are randomized controlled trials with a physical therapy crossover. That means that initially, both would have randomly assigned the patient to get either the treatment or physical therapy. However, in both studies the Physical therapy allotments are full, so in both, you can go right to the treatment.
The treatment, in this case, is bone marrow concentrate (aka a same-day stem cell therapy). In the case of the ACL, this is injected into both bundles of the ligament via x-ray guidance (fluoroscopy). For rotator cuff tears, the treatment involves injection via ultrasound.
Who is a candidate? Patients with partial to full-thickness non-retracted tears of either the ACL or rotator cuff who still have chronic pain or inability to return to full activity. Due to the fact that only certain tear types qualify, you need to have an MRI of the knee or shoulder.
Study Costs
The stem cell care in both studies is free of charge. You just have to qualify for the study based on the inclusion and exclusion criteria. Any costs of dealing with complications, even though very unlikely, are borne by the patient. The care is delivered at our Colorado clinic only, but we do accept out of town patients who qualify.
How Do You Determine If You or a Loved One Is a Candidate?
The contact person is our full-time research coordinator at Regenexx-HQ in Colorado, Ehren Dodson, Ph.D. Her email is edodson@regenexx.com.
The upshot? We would like to get both of these studies completed, so if you have a patient or know of someone with either an ACL tear or rotator cuff tear, send them our way to see if they qualify. The study-related care doesn’t cost the patient anything and we’re excited to see our final few patients in both projects!
As you may know, we’ve been performing lab-based and clinical research for many years. Two of our most recent studies are for patients with ACL and rotator cuff tears. Both of these research projects will soon be completed, so this is your last chance to get somebody advanced bone marrow concentrate care as part of a study.
Study Designs
Both of these studies are randomized controlled trials with a physical therapy crossover. That means that initially, both would have randomly assigned the patient to get either the treatment or physical therapy. However, in both studies the Physical therapy allotments are full, so in both, you can go right to the treatment.
The treatment, in this case, is bone marrow concentrate (aka a same-day stem cell therapy). In the case of the ACL, this is injected into both bundles of the ligament via x-ray guidance (fluoroscopy). For rotator cuff tears, the treatment involves injection via ultrasound.
Who is a candidate? Patients with partial to full-thickness non-retracted tears of either the ACL or rotator cuff who still have chronic pain or inability to return to full activity. Due to the fact that only certain tear types qualify, you need to have an MRI of the knee or shoulder.
Study Costs
The stem cell care in both studies is free of charge. You just have to qualify for the study based on the inclusion and exclusion criteria. Any costs of dealing with complications, even though very unlikely, are borne by the patient. The care is delivered at our Colorado clinic only, but we do accept out of town patients who qualify.
How Do You Determine If You or a Loved One Is a Candidate?
The contact person is our full-time research coordinator at Regenexx-HQ in Colorado, Ehren Dodson, Ph.D. Her email is edodson@regenexx.com.
The upshot? We would like to get both of these studies completed, so if you have a patient or know of someone with either an ACL tear or rotator cuff tear, send them our way to see if they qualify. The study-related care doesn’t cost the patient anything and we’re excited to see our final few patients in both projects!